[ERCC1 and lung cancer].
ERCC1 plays a critical role in the repair of lesions in DNA induced by cisplatin. It has been demonstrated that, in patients with resected NSCLC, those with ERCC1-negative tumours had greater benefit from adjuvant chemotherapy than patients with ERCC1-positive tumours. On the other hand, patients with ERCC1-positive tumours have a better prognosis. ERCC1 can be evaluated either by the level of protein expression on immunohistochemical analysis or by quantification of its mRNA expression. At present ERCC1 appears to be a promising biomarker for predicting the benefit of cisplatin based chemotherapy and its modulation could allow sensitisation of tumour cells to this drug. Its use in daily clinical practice requires a further stage of prospective validation studies which are already in progress in patients both with completely resected NSCL or metastatic disease.
Planchard
D
D
Unité Inserm U981, institut Gustave-Roussy, 114, rue Edouard-Vaillant, 94805 Villejuif cedex, France.
Olaussen
K-A
KA
Soria
J-C
JC
D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000032:analysis*; D002289:Carcinoma, Non-Small-Cell Lung / Q000473:pathology* / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000627:therapeutic use; D004260:DNA Repair; D004268:DNA-Binding Proteins / Q000032:analysis*; D004720:Endonucleases / Q000032:analysis*; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology* / Q000601:surgery; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D011379:Prognosis
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D004268:DNA-Binding Proteins; C071447:ERCC1 protein, human; D004720:Endonucleases; D002945:Cisplatin